The tens of billions of diabetes drug market will usher in strong competitors

In recent years, with the changes in people's life>
.
The industry predicts that according to the current growth trend, there will be 700 million diabetic patients in the world by 2045
.
In the context of the increasing number of diabetic patients, the field of diabetes treatment is also becoming a huge potential market
.
For example, in China, with the increase in the prevalence of diabetes, the improvement of people's living standards and the improvement of medical standards, the scale of China's diabetes drug market is expanding year by year.
It is estimated that the market size will be close to 43.
7 billion yuan by 2022
.
The huge market will naturally attract more companies' attention
.
It is understood that the current competition for diabetes drugs under research is quite fierce, and more and more companies are applying for the listing of drugs in this field
.
According to reports, Microchip's new class 1 diabetes drug "siglita sodium" has been approved recently and is expected to be approved for marketing in the near future
.
It is reported that Chiglitazar Sodium is a new PPAR full agonist with a non-TZD structure that can balance and not over-activate the three receptor subtypes of PPARα, δ and γ
.
In July 2021, Microchip Biosciences issued an announcement stating that Science Bulletin published the results of two confirmatory Phase 3 clinical trials
.
The results showed that after 24 weeks of treatment with sitaglipta sodium, the absolute value of glycosylated hemoglobin (HbA1c) was reduced by 1.
32%~1.
52% compared with before treatment.
Both doses showed continuous and clinically significant blood glucose control effects
.
While effectively controlling HbA1c, the two dose groups of sitaglipta sodium showed superiority in fasting blood glucose, insulin resistance index, 2-hour postprandial blood glucose, free fatty acids, triglycerides and a series of secondary efficacy endpoints.
Trends in the efficacy of control drugs
.
In addition, Microchip Biosciences announced at the end of 2020 that it had reached a strategic cooperation with Hisun Pharmaceutical, and granted Hisun Pharmaceutical the exclusive right to promote Siglita sodium tablets in 19 provinces and regions in China
.
The industry believes that based on the good efficacy of the drug, the future sales prospects of the drug will be very impressive
.
In addition to Microchip, many domestic pharmaceutical companies, including Hengrui Pharmaceuticals, Kelun Pharmaceuticals, Hua Medicine, Guizhou Bailing and other companies, are also actively participating in the development and introduction of drugs in the field of diabetes drugs
.
For example, Huadong Medicine announced that it had signed an exclusive product commercialization agreement with multinational pharmaceutical company Takeda (Takeda Pharmaceutical), and obtained Takeda Pharmaceutical’s innovative product Alogliptin benzoate (trade name: Nisina) in mainland China.
Exclusive commercialization rights
.
It is reported that after the completion of the transaction, Huadong Medicine will have the commercialization rights of Nisina in China, and Takeda Pharmaceuticals will continue to be responsible for the production and supply of Nisina
.
According to data, the alogliptin benzoate tablets in this transaction are dipeptidyl peptidase-4 (DPP-4) inhibitors for the treatment of type 2 diabetes
.
At present, only the original research product of Alogliptin benzoate tablets is sold in the domestic market
.
In addition, the CDE website shows that in September this year, Huadong Medicine also submitted a listing application for liraglutide injection and was contracted
.
This is the first domestically produced liraglutide biosimilar drug.
The data shows that the original company of liraglutide is Novo Nordisk, which is a human glucagon-like peptide-1 (GLP-1) receptor Agonists can enhance insulin secretion in a glucose concentration-dependent manner, inhibit glucagon secretion, delay gastric emptying, and reduce food intake through central appetite suppression, thereby lowering blood sugar
.
The industry believes that with the successive launch of domestically approved products and the continuous introduction of foreign drugs, patients with diabetes will use more effective and targeted drugs in the future
.
But at the same time, competition among companies in the drug market is expected to become increasingly fierce
.